Skip to content

Price / sales at other companies

Opko Health logo
Opko HealthOPK
1.5×-0.1×
AMP
Amphastar PharmaceuticalsAMPH
1.2×-0.7×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.5×-5.5×
Theravance Biopharma logo
Theravance BiopharmaTBPH
7.6×+0.8×
HRO
HarrowHROW
4.9×+0.4×
Precigen logo
PrecigenPGEN
102.3×

Other financials

Income statement

See full
Revenue$58.3M+104%
Gross profit$46.3M+86.8%
Operating income-$15.5M+80.4%
Net income-$30.4M+67.8%
EPS (diluted)-$0.37+71.8%

Balance sheet

See full
Cash & equivalents$180.9M-14.8%
Total debt$166.3M-18.3%
Total equity-$337.0M+0.4%
Total assets$305.1M+3.7%

Cash flow

See full
Operating cash flow-$15.6M+81.6%
CapEx$61.0K+239%
Free cash flow-$15.7M+81.5%

Valuation

See full
Market cap$846.21M+16.3%
Enterprise value$831.61M+15.7%

Profitability

See full
Gross margin84.9%-1.3pp
Operating margin-47.1%-21.9pp
Net margin-76.8%-34.5pp
FCF margin-47.7%-22.1pp

Returns & leverage

See full
Return on equity-147.9%
Debt / equity5.6×
Current ratio2.2×-1.4×

Where this comes from

Calculated from Phathom Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s price / sales?
Phathom Pharmaceuticals, Inc. (PHAT) reported price / sales of 4.3× in Q1 2026.
How has Phathom Pharmaceuticals, Inc.'s price / sales changed year-over-year?
Phathom Pharmaceuticals, Inc.'s price / sales decreased by 19.9% year-over-year, from 5.3× to 4.3×.
What is the long-term trend for Phathom Pharmaceuticals, Inc.'s price / sales?
Over 2 years (2023 to 2025), Phathom Pharmaceuticals, Inc.'s price / sales has grown at a -90.6% compound annual growth rate (CAGR), from 767× to 6.7×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.